About R

Triple Agonist Mechanism: It targets three distinct metabolic receptors simultaneously: GLP-1 (glucagon-like peptide-1) to control appetite and slow digestion, GIP (glucose-dependent insulinotropic polypeptide) to improve insulin response, and glucagon to increase energy expenditure and fat burning. Development Status: Developed by Eli Lilly, R is currently undergoing late-stage Phase 3 clinical trials for weight management and metabolic health, with potential FDA approval applications anticipated around early 2027. Regulatory Notice: Outside of authorized clinical trials, it is not an FDA-approved medication. Vials sold online are strictly intended as reference or research materials for laboratory analysis and are not approved for human or animal consumption.